2 Participants Needed

Gene Transfer with SRP-6004 for Limb-Girdle Muscular Dystrophy

No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, if you require chronic drug treatment that the investigator believes poses a risk for gene transfer, it might be a concern.

What data supports the effectiveness of the treatment SRP-6004 for Limb-Girdle Muscular Dystrophy?

Research on a similar treatment, SRP-9005, showed that gene transfer therapy in mice with a similar condition led to improvements in muscle function and structure, suggesting potential benefits for SRP-6004 in humans.12345

Is SRP-6004 gene therapy safe for humans?

Research on similar gene therapies using adeno-associated virus (AAV) vectors, like those for other muscular dystrophies, shows they are generally well-tolerated with no significant toxicity observed in animal studies. However, there are concerns about immune responses, so safety measures are important to minimize risks.16789

How does the treatment SRP-6004 differ from other treatments for limb-girdle muscular dystrophy?

SRP-6004 is unique because it uses gene transfer therapy to deliver a functional version of the γ-sarcoglycan gene directly into muscle cells, aiming to correct the underlying genetic defect causing limb-girdle muscular dystrophy. This approach is different from traditional treatments as it targets the root cause of the disease rather than just managing symptoms.1251011

What is the purpose of this trial?

This trial is testing the safety of a medicine called SRP-6004, given through a vein, in people who can walk but have a specific type of muscular dystrophy (LGMD2B/R2).

Research Team

MD

Medical Director

Principal Investigator

Sarepta Therapeutics, Inc.

Eligibility Criteria

This trial is for ambulatory individuals with Limb Girdle Muscular Dystrophy, Type 2B/R2. Participants must have specific genetic mutations related to the condition, be able to perform motor tests, and not have high levels of certain antibodies. They can't join if they've had recent gene therapy or other investigational treatments, significant health issues, or need chronic drug treatment that could pose risks.

Inclusion Criteria

I have specific genetic mutations in the DYSF gene.
My arm and leg muscles are suitable for biopsy.
I can participate in tests that measure my muscle movements.
See 2 more

Exclusion Criteria

Presence of any other clinically significant illness, medical condition, or requirement for chronic drug treatment that in the opinion of the Investigator creates unnecessary risk for gene transfer.
Abnormality in protocol-specified diagnostic evaluations or laboratory tests.
Exposure to gene therapy, investigational medication, or other protocol-specified treatment within the protocol specified time limits.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive a single IV infusion of SRP-6004 on Day 1

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

12 weeks

Treatment Details

Interventions

  • SRP-6004
Trial Overview The study is testing SRP-6004's safety when given through an IV infusion to people who can walk but have LGMD2B/R2. It aims to understand how well participants tolerate this potential new treatment and its effectiveness in treating their muscular dystrophy.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: SRP-6004Experimental Treatment1 Intervention
Participants will receive single IV infusion of SRP-6004 on Day 1.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Sarepta Therapeutics, Inc.

Lead Sponsor

Trials
54
Recruited
34,000+

Findings from Research

Thigh muscle fat replacement measured by proton density fat fraction (PDFF) using MRI is a sensitive indicator of disease progression in patients with limb-girdle muscular dystrophy autosomal recessive type 12 (LGMDR12), particularly in those with intermediate-stage fat replacement, showing significant changes within just one year.
Biodex isometric dynamometry effectively captures the decline in muscle strength over one year in LGMDR12 patients, making it a valuable outcome measure for future clinical trials, while traditional clinical measures like the 6-minute walk distance and 10-meter walk test were less effective in detecting changes.
Prospective Natural History Study in 24 Adult Patients With LGMDR12 Over 2 Years of Follow-up: Quantitative MRI and Clinical Outcome Measures.De Wel, B., Huysmans, L., Peeters, R., et al.[2023]
This study identified a new genetic locus for limb-girdle muscular dystrophy (LGMD) on chromosome 2p, specifically linked to markers D2S134 and D2S136, after excluding other known loci.
The affected individuals from two large inbred families exhibited similar symptoms, with muscle weakness starting in the pelvic girdle during late adolescence and a generally slow progression of the disease.
A gene for autosomal recessive limb-girdle muscular dystrophy maps to chromosome 2p.Bashir, R., Strachan, T., Keers, S., et al.[2022]
The study developed a human codon-optimized version of microutrophin (µUtrn) that showed robust muscle expression and functional improvement in mdx mice, indicating its potential as a safer alternative to traditional dystrophin gene therapy for Duchenne muscular dystrophy (DMD).
Long-term administration of rAAV9-µUtrn resulted in lower immunogenicity and no adverse effects in toxicity studies, supporting its safety for clinical development as a gene therapy for DMD.
Therapeutic potential of highly functional codon-optimized microutrophin for muscle-specific expression.Starikova, AV., Skopenkova, VV., Polikarpova, AV., et al.[2022]

References

Systemic γ-sarcoglycan AAV gene transfer results in dose-dependent correction of muscle deficits in the LGMD 2C/R5 mouse model. [2023]
Prospective Natural History Study in 24 Adult Patients With LGMDR12 Over 2 Years of Follow-up: Quantitative MRI and Clinical Outcome Measures. [2023]
Novel Variants of ANO5 in Two Patients With Limb Girdle Muscular Dystrophy: Case Report. [2022]
Limb-girdle muscular dystrophies - international collaborations for translational research. [2022]
A gene for autosomal recessive limb-girdle muscular dystrophy maps to chromosome 2p. [2022]
Therapeutic potential of highly functional codon-optimized microutrophin for muscle-specific expression. [2022]
Systemic AAV9.BVES delivery ameliorates muscular dystrophy in a mouse model of LGMDR25. [2023]
Gene therapy for primary myopathies: literature review and prospects. [2023]
Unmet needs and evolving treatment for limb girdle muscular dystrophies. [2022]
10.United Statespubmed.ncbi.nlm.nih.gov
Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy type 2A. [2012]
11.United Statespubmed.ncbi.nlm.nih.gov
Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security